AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient

8Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There are more than 10,000 individual rare diseases and most are without therapy. Personalized genetic therapy represents one promising approach for their treatment. We present a road map for individualized treatment of an ultra-rare disease by establishing a gene replacement therapy developed for a single patient with hereditary spastic paraplegia type 50 (SPG50). Through a multicenter collaboration, an adeno-associated virus-based gene therapy product carrying the AP4M1 gene was created and successfully administered intrathecally to a 4-year-old patient within 3 years of diagnosis as part of a single-patient phase 1 trial. Primary endpoints were safety and tolerability, and secondary endpoints evaluated efficacy. At 12 months after dosing, the therapy was well tolerated. No serious adverse events were observed, with minor events, including transient neutropenia and Clostridioides difficile gastroenteritis, experienced but resolved. Preliminary efficacy measures suggest a stabilization of the disease course. Longer follow-up is needed to confirm the safety and provide additional insights on the efficacy of the therapy. Overall, this report supports the safety of gene therapy for SPG50 and provides insights into precision therapy development for rare diseases. Clinical trial registration: NCT06069687.

References Powered by Scopus

Patient-customized oligonucleotide therapy for a rare genetic disease

551Citations
N/AReaders
Get full text

Inter-and intra-rater reliability of the Modified Ashworth Scale: A systematic review and meta-analysis

277Citations
N/AReaders
Get full text

Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy

138Citations
N/AReaders
Get full text

Cited by Powered by Scopus

International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease

0Citations
N/AReaders
Get full text

“Trafficking Disorders: Phenotypical Similarities and Differences With Other IMDs”

0Citations
N/AReaders
Get full text

Gene-replacement therapy in neurodevelopmental disorders: progress and challenges

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dowling, J. J., Pirovolakis, T., Devakandan, K., Stosic, A., Pidsadny, M., Nigro, E., … Gray, S. J. (2024). AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient. Nature Medicine, 30(7), 1882–1887. https://doi.org/10.1038/s41591-024-03078-4

Readers' Seniority

Tooltip

Researcher 5

63%

PhD / Post grad / Masters / Doc 3

38%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 3

38%

Earth and Planetary Sciences 2

25%

Medicine and Dentistry 2

25%

Materials Science 1

13%

Article Metrics

Tooltip
Mentions
News Mentions: 11
Social Media
Shares, Likes & Comments: 18

Save time finding and organizing research with Mendeley

Sign up for free